We are international
Donate
TEXT SIZE   


Dr. Richardson - A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
USA
12.02.10


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles